# US 2026/0091066 A1 · Method for preventing infection of a healthy person or a healthy animal with a virus that uses ace2 as a receptor, binding inhibitor and medical device

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0091066 A1
- Document ID: US20260091066A1
- Status: Published application
- Kind: A1
- Application number: 19/413,925
- Filed: 2025-12-09
- Published: 2026-04-02
- Earliest claimed: 2020-07-17
- Assignees: Dexon Pharmaceuticals Inc.
- Applicants: Dexon Pharmaceuticals Inc.
- Inventors: Shoji KOGA
- Web page: https://patentgrep.com/patent/US20260091066A1

## CPC

- A61K 35/51: Umbilical cord; Umbilical cord blood; Umbilical stem cells
- A61K 35/32: Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
- A61K 35/35: Fat tissue; Adipocytes; Stromal cells; Connective tissues (adipose-derived stem cells A61K35/28; collagen A61K38/39)
- A61K 38/4813: {Exopeptidases (3.4.11. to 3.4.19)}
- A61P 31/14: for RNA viruses
- C12N 5/0663: {Bone marrow mesenchymal stem cells (BM-MSC)}
- C12N 5/0664: {Dental pulp stem cells, Dental follicle stem cells}
- C12N 5/0665: {Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood}
- C12N 5/0667: {Adipose-derived stem cells [ADSC]; Adipose stromal stem cells}
- C12Y 304/15001: Peptidyl-dipeptidase A (3.4.15.1)
- C12Y 304/17023: Angiotensin-converting enzyme 2 (3.4.17.23)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

A composition containing a culture supernatant of dental pulp-derived stem cells, adipose-derived stem cells, umbilical cord-derived stem cells or immortalized stem cells thereof in which the composition contains angiotensin-converting enzyme 2 (ACE2) and is used for administration to a healthy person or a healthy animal for preventing infection of the healthy person or the healthy animal with a virus that uses ACE2 as a receptor can be used as a medicine for preventing infection with a virus that uses ACE2 as a receptor, such as COVID-19, or the like when administered to a healthy person or a healthy animal.

## Claims

### Claim 1

A binding inhibitor comprising the following binding inhibitor (1) or binding inhibitor (2);
wherein the binding inhibitor (1) comprises a culture supernatant of dental pulp-derived stem cells, adipose-derived stem cells, umbilical cord-derived stem cells or immortalized stem cells thereof, and angiotensin-converting enzyme 2 (ACE2); or
wherein the binding inhibitor (2) comprises microparticles from a culture supernatant of dental pulp-derived stem cells, adipose-derived stem cells, umbilical cord-derived stem cells or immortalized stem cells thereof,
wherein the microparticles contain ACE2, and
the binding inhibitor (2) is used for administration to a healthy person or a healthy animal and
inhibits binding of a virus that uses ACE2 as a receptor to ACE2 of a human or a nonhuman animal.

### Claim 2 (depends on 1)

A medical device containing the binding inhibitor according to claim 1.

### Claim 3 (depends on 1)

The binding inhibitor according to claim 1, wherein the microparticles are exosomes.

### Claim 4 (depends on 1)

The binding inhibitor according to claim 1, wherein the microparticles are microparticles purified from the culture supernatant.

### Claim 5 (depends on 1)

The binding inhibitor according to claim 1, wherein the binding inhibitor contains 0.01×108 particles/ml or more of the microparticles.

### Claim 6 (depends on 1)

The binding inhibitor according to claim 1, wherein the binding inhibitor contains 100 ng/ml or more of ACE2.

### Claim 7 (depends on 1)

The binding inhibitor according to claim 1, wherein the dental pulp-derived stem cells, the adipose-derived stem cells or the umbilical cord-derived stem cells used for the culture supernatant are not genetically modified.

### Claim 8 (depends on 1)

The binding inhibitor according to claim 1, wherein the binding inhibitor contains 100 ng/ml or more of ACE2.

### Claim 9 (depends on 1)

The binding inhibitor according to claim 1, wherein the dental pulp-derived stem cells, the adipose-derived stem cells or the umbilical cord-derived stem cells are human dental pulp-derived stem cells, human adipose-derived stem cells or human umbilical cord-derived stem cells.
